Recruiting

Testing a new diabetes medication given twice monthly versus daily pills

Plain-English translation of NCT07019012 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated June 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This trial is testing a new diabetes medication called cofrogliptin that you would take once every two weeks, in addition to medications you're likely already on (metformin and dapagliflozin). The study will compare how well this new medication works compared to another daily pill called linagliptin at controlling blood sugar. Both groups will be followed for 24 weeks to see which approach works better.

Many people with type 2 diabetes struggle to control their blood sugar even when taking two medications together. This trial is testing whether adding this new medication — which requires fewer injections or doses than daily pills — could be a better or more convenient option for people whose diabetes isn't well controlled.

Do you qualify?

You likely qualify if…

you have been diagnosed with type 2 diabetes and your blood sugar is not well controlled even with two current medications
you have been taking metformin (at least 1000–1500 mg daily) for at least 12 weeks and dapagliflozin (10 mg daily) for at least 12 weeks
your HbA1c (a measure of average blood sugar over three months) is between 7.0% and 10.0%
you are 18 years or older and able to understand and sign an informed consent form
you have a body mass index (BMI) of 40 or less and normal kidney function (eGFR of at least 60)

You likely don't qualify if…

you have type 1 diabetes or secondary diabetes (diabetes caused by another condition)
you have had a heart attack, stroke, or unstable chest pain in the last three months
you have uncontrolled high blood pressure (systolic 160 mmHg or higher, or diastolic 100 mmHg or higher)
you have moderate to severe liver disease or a history of pancreatitis
you are allergic to any of the study medications or have HIV, cancer, or other serious conditions that your doctor feels would affect your ability to participate safely

What participation looks like

If you join this study, you'll be randomly assigned to receive either the new medication (cofrogliptin) added to your current two medications, or a daily pill (linagliptin) added to your current two medications. You'll visit the clinic multiple times over 24 weeks for blood tests and check-ups to measure how well your blood sugar is controlled. You'll also be asked to check your own blood sugar at home using a meter and keep records, and to maintain the same diet and exercise habits throughout the study.

AI-generated summary from trial data · Jun 16, 2026 · Not medical advice

Trial locations(2 sites)

China

Wuhan University People's Hospital, Wuhan, Hubei